Provided by Tiger Trade Technology Pte. Ltd.

Celularity Inc.

0.8001
+0.03314.31%
Post-market: 0.83450.0344+4.31%19:30 EDT
Volume:26.35K
Turnover:21.29K
Market Cap:23.07M
PE:-0.22
High:0.8500
Open:0.7700
Low:0.7305
Close:0.7670
52wk High:4.01
52wk Low:0.5601
Shares:28.84M
Float Shares:18.87M
Volume Ratio:0.67
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5900
EPS(LYR):-3.5900
ROE:-6367.24%
ROA:-30.93%
PB:-0.61
PE(LYR):-0.22

Loading ...

Celularity files Form 3 for Philip & Daniele Barach Family Trust beneficial ownership

Reuters
·
Apr 25

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

GlobeNewswire
·
Apr 21

Celularity closes biomaterials asset sale and license deal with NexGel for $13.3 million

Reuters
·
Apr 21

BRIEF-Celularity Announces Receipt Of Nasdaq Notice Regarding Late Form 10-K Filing

Reuters
·
Apr 18

Top News Today/Canada: Liberals Within Reach of Majority Government

Dow Jones
·
Apr 09

Top News Today/Canada: March Manufacturing PMI Slips to 50

Dow Jones
·
Apr 02

Celularity delays annual report filing, cites liquidity and accounting staffing constraints

Reuters
·
Apr 01

Nexgel Inc - Consideration Includes $15 Mln Upfront Cash and up to $20 Mln in Milestone Payments

THOMSON REUTERS
·
Mar 12

Nexgel Inc - Deal Expected to Triple Annual Revenue to $35 Mln and Make Company Profitable Upon Closing

THOMSON REUTERS
·
Mar 12

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

GlobeNewswire
·
Mar 12

Celularity reiterates strategic commercialization partnership with NEXGEL

TIPRANKS
·
Mar 12

Nexgel Inc - Expects to Close $14.9 Mln in Additional Financing in Q1 or Early Q2 2026

THOMSON REUTERS
·
Mar 10

Nexgel Inc - Deal Expected to Triple Annual Revenue to $35 Mln and Make Nexgel Profitable

THOMSON REUTERS
·
Mar 10

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

GlobeNewswire
·
Mar 10

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

THOMSON REUTERS
·
Mar 10

Celularity Inc - Organizational Realignment Reduces Operating Expenses and Sharpens Longevity Therapeutics Focus

THOMSON REUTERS
·
Mar 10

Celularity Inc - Retains Exclusive Manufacturing Rights for Licensed Biomaterials Portfolio

THOMSON REUTERS
·
Mar 10

Celularity Inc - Enters Strategic Commercialization Partnership for Biomaterials Portfolio

THOMSON REUTERS
·
Mar 10

Celularity Inc - Personnel Associated With Biomaterials Activities to Transition to Commercial Partner; Further Workforce Reduction

THOMSON REUTERS
·
Mar 10

BRIEF-Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026 - SEC Filing

Reuters
·
Mar 06